APA (7th ed.) Citation

FB, R., SW, C., JV, M., NRB, B., LLA, C., E, A., . . . B, E. (2024). Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: An updated meta-analysis and meta-regression. Current medical research and opinion, 40(7), 1103. https://doi.org/10.1080/03007995.2024.2363971

Chicago Style (17th ed.) Citation

FB, Rivera, et al. "Safety Profile of Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors Alirocumab and Evolocumab: An Updated Meta-analysis and Meta-regression." Current Medical Research and Opinion 40, no. 7 (2024): 1103. https://doi.org/10.1080/03007995.2024.2363971.

MLA (9th ed.) Citation

FB, Rivera, et al. "Safety Profile of Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors Alirocumab and Evolocumab: An Updated Meta-analysis and Meta-regression." Current Medical Research and Opinion, vol. 40, no. 7, 2024, p. 1103, https://doi.org/10.1080/03007995.2024.2363971.